Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial): outcome at 3 years old.
Saturday, April 26, 2025
2:15pm – 2:30pm HST
Location: Convention Center: Kalākaua Ballroom C (Level 4)
Yoshiaki Sato, Nagoya University Hospital, Nagoya, Aichi, Japan; Yukako Muramatsu, Nagoya University Hospital, Nagoya, Aichi, Japan; Shinobu Shimizu, Nagoya University Hospital, Nagoya, Aichi, Japan; Kazuto Ueda, Nagoya University, Nagoya, Aichi, Japan; ryosuke Miura, Nagoya university, Nagoya, Aichi, Japan; Toshihiko Suzuki, Division of Neonatology Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, Aichi, Japan; KENNOSUKE TSUDA, Nagoya City University, London, England, United Kingdom; Osuke Iwata, Nagoya City University, Nagoya, Aichi, Japan; Hiroyuki Kidokoro, Nagoya University, Nagoya, Aichi, Japan
Presenting Author(s)
Yoshiaki Sato, MD, PhD (he/him/his)
Director, Associate Clinical Professor Nagoya University Hospital Nagoya, Aichi, Japan
Disclosure(s):
Yoshiaki Sato, MD, PhD: Life Science Institute, Inc. (Terminated, March 31, 2023) (Products/Services: Contractor including contracted research); S-Quatre Corporation (Ongoing) (Products/Services: Contractor including contracted research)
